Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

RSS icon

FDA approves Boston Scientific’s Emblem MRI S-ICD system

The FDA approved the Emblem MRI subcutaneous implantable defibrillator system (Boston Scientific) on August 9. The agency also approved magnetic resonance labeling for previously implanted Emblem S-ICD systems.

Thumbnail

Changing Strategy: Edging Stable Chest Pain Diagnosis Out of ‘a Primitive Age of Evidence’

Is a new testing strategy evolving for the evaluation of patients with stable chest pain? 

Thumbnail

Another Building Block in the Wall: Analysis Suggests Expanded Role for CCTA in Heart Disease Treatment

Analysis Suggests Expanded Role for CCTA in Heart Disease Treatment

USPSTF outlines research plan for examining the use of ECG to screen for CVD risk and atrial fibrillation

After receiving comments from the public, the U.S. Preventive Services Task Force (USPSTF) recently released its final research plan for screening for cardiovascular disease risk and atrial fibrillation with electrocardiography (ECG).

Corpath System to be Featured for Complex Interventions at SDCI 2016: San Diego Cardiovascular Interventions Course

WALTHAM, MA – July 5, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced that its CorPath® System will be highlighted in several presentations on new therapies and techniques for the treatment of high-risk patients with complex cardiovascular disease at SDCI 2016: San Diego Cardiovascular Interventions Course, July 8 and 9, at the Estancia La Jolla Hotel & Spa, La Jolla, CA. Corindus' CorPath System, the first FDA-cleared medical device to bring robotically-assisted precision to radial, coronary and peripheral procedures, will be featured in two live robotic-assisted complex percutaneous coronary interventions (PCIs) during the course.

Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths

DUBLIN - July 13, 2016 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in longer, 150 mm lengths. The new 150 mm length balloon, available in four, five, and six mm diameters, will provide greater treatment options for long lesions in patients with peripheral artery disease (PAD). 

University of Chicago Medicine Creating High-Tech Arrhythmia Technology Suite with Stereotaxis Niobe® ES System

July 13, 2016 — Stereotaxis, Inc., a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe ES remote magnetic navigation system as part of its vision to create a cutting-edge arrhythmia technology suite. 

Good Samaritan Hospital First on the West Coast to Offer Naturally Dissolving Heart Stent to Patients with Coronary Artery Disease

LOS ANGELES, July 12, 2016 /PRNewswire-USNewswire/ --  Good Samaritan Hospital is the first hospital on the West Coast to offer patients with coronary artery disease (CAD) a first-of-its-kind dissolving heart stent.   Abbott's Absorb™ dissolving heart stent is a drug eluting coronary stent that dissolves, completely and naturally, in the body over time.  Absorb™ treats coronary artery disease like a metallic stent, propping the diseased vessel open to restore1 blood flow, but then disappears after the artery is healed, leaving no metal behind to restrict natural vessel motion.

Displaying 1569 - 1576 of 2645

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.